#KEYTRUDA® (#pembrolizumab) plus #LENVIMA® (#Lenvatinib) Combination Demonstrated Clinically Meaningful #Tumor Response Rates in Unresectable #HepatocellularCarcinoma and Advanced #RenalCellCarcinoma $MRK https://t.co/jRu8HGbkM4